ロード中...
Somatic mutations of the epidermal growth factor receptor and non‐small‐cell lung cancer
Frequent overexpression of epidermal growth factor receptor (EGFR) in non‐small‐cell lung cancer (NSCLC) makes EGFR a new therapeutic target. Two specific EGFR tyrosine kinase inhibitors, gefitinib (ZD1839, Iressa) and erlotinib (OSI‐774, Tarceva), have been developed and approved by the US Food and...
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BMJ Group
2007
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2598028/ https://ncbi.nlm.nih.gov/pubmed/17158592 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jmg.2006.046102 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|